Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License AgreementBusiness Wire • 05/18/21
Glaukos Corp (GKOS) CEO Tom Burns on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/08/21
Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/28/21
Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of PresbyopiaBusiness Wire • 04/22/21
Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5Business Wire • 04/14/21
Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening InitiativesBusiness Wire • 03/08/21
Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial ResultsBusiness Wire • 02/25/21
Glaukos Announces Positive Phase 3 Trial Results for iLink™ Epi-on Investigational Therapy That Met the Primary Efficacy EndpointBusiness Wire • 02/25/21
Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25Business Wire • 02/04/21
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net SalesBusiness Wire • 01/13/21
U.S. IDE Trial Results for Glaukos' iStent infinite™ Show Substantial Reduction in IOPBusiness Wire • 01/13/21
Glaukos' iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b StudyBusiness Wire • 01/13/21
Glaukos (GKOS) Up 24.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/20
Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)Zacks Investment Research • 11/10/20